STUDY: In Vitro Antimicrobial Activity of OMN51 Against MDR Pseudomonas aeruginosa Isolated from People with Cystic Fibrosis

Omnix Medical tested its novel antimicrobial peptide, OMN51, on clinical isolates of multi-drug-resistant Pseudomonas aeruginosa collected from cystic fibrosis patients, in collaboration with Beilinson – Rabin Medical Center.
The results demonstrated rapid bactericidal activity with complete clearance within 1-8 hours and minimal cytotoxicity to human cells. 
OMN51 represents a first-in-class, membrane-targeting therapeutic showing promise against MDR P. aeruginosa.
 
 

Authors: Moshe Heching, Moshe Cohen-Kutner, Haim Ben-Zvi, Liora Slomianksy, Elital Chass Maurice, Noa Nur Maymon, Shira Mandel, Michal Oholy, Rony Moses, Michal Lavon, Katherine Kaufman, Orel Mayost Lev-Ari,Tamar Shachar, Joel Weinberg, Mordechai R. Kramer and Niv Bachnoff.

 

More To Explore

Contact Us

Reach US

Linkedin Twitter

A-2-Z - Digital Accessibility and Marketing

 

Omnix Medical Ltd. is committed to making its website and all its electronic information easier to use and more accessible for people with disabilities. The company’s website was created and/or updated according to the provisions of the Equal Rights for People with Disabilities Law, 5748-1998, and the delegated legislation stemming from it, and it fully complies with the W3C Web Content Accessibility Guidelines 2.0, AA level.


Omnix Medical Ltd. will continue its efforts to constantly improve the accessibility of its website and information in the belief that it is our collective moral obligation to allow seamless, accessible, and unhindered use also for those of us with disabilities.

  

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).